|
rdf:type |
|
|
lifeskim:mentions |
|
|
pubmed:issue |
1
|
|
pubmed:dateCreated |
2006-12-4
|
|
pubmed:abstractText |
Consumption of caffeine, an adenosine receptor antagonist, was found to be inversely associated with the incidence of Alzheimer's disease. Moreover, caffeine protects cultured neurons against beta-amyloid-induced toxicity, an effect mimicked by adenosine A(2A) but not A(1) receptor antagonists. We now tested if caffeine administration would prevent beta-amyloid-induced cognitive impairment in mice and if this was mimicked by A(2A) receptor blockade. One week after icv administration of the 25-35 fragment of beta-amyloid (Abeta, 3 nmol), mice displayed impaired performance in both inhibitory avoidance and spontaneous alternation tests. Prolonged treatment with caffeine (1 mg/ml) had no effect alone but prevented the Abeta-induced cognitive impairment in both tasks when associated with acute caffeine (30 mg/kg) 30 min treatment before Abeta administration. The same protective effect was observed after subchronic (4 days) treatment with daily injections of either caffeine (30 mg/kg) or the selective adenosine A(2A) receptor antagonist SCH58261 (0.5 mg/kg). This provides the first direct in vivo evidence that caffeine and A(2A) receptor antagonists afford a protection against Abeta-induced amnesia, which prompts their interest for managing Alzheimer's disease.
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
http://linkedlifedata.com/resource/pubmed/chemical/5-amino-7-(2-phenylethyl)-2-(2-furyl...,
http://linkedlifedata.com/resource/pubmed/chemical/Adenosine A2 Receptor Antagonists,
http://linkedlifedata.com/resource/pubmed/chemical/Amyloid beta-Peptides,
http://linkedlifedata.com/resource/pubmed/chemical/Caffeine,
http://linkedlifedata.com/resource/pubmed/chemical/Neuroprotective Agents,
http://linkedlifedata.com/resource/pubmed/chemical/Peptide Fragments,
http://linkedlifedata.com/resource/pubmed/chemical/Phosphodiesterase Inhibitors,
http://linkedlifedata.com/resource/pubmed/chemical/Pyrimidines,
http://linkedlifedata.com/resource/pubmed/chemical/Receptor, Adenosine A2A,
http://linkedlifedata.com/resource/pubmed/chemical/Triazoles,
http://linkedlifedata.com/resource/pubmed/chemical/amyloid beta-protein (25-35)
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Jan
|
|
pubmed:issn |
0014-4886
|
|
pubmed:author |
|
|
pubmed:issnType |
Print
|
|
pubmed:volume |
203
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
241-5
|
|
pubmed:dateRevised |
2010-11-18
|
|
pubmed:meshHeading |
pubmed-meshheading:17007839-Adenosine A2 Receptor Antagonists,
pubmed-meshheading:17007839-Alzheimer Disease,
pubmed-meshheading:17007839-Amnesia,
pubmed-meshheading:17007839-Amyloid beta-Peptides,
pubmed-meshheading:17007839-Animals,
pubmed-meshheading:17007839-Avoidance Learning,
pubmed-meshheading:17007839-Brain,
pubmed-meshheading:17007839-Caffeine,
pubmed-meshheading:17007839-Cognition Disorders,
pubmed-meshheading:17007839-Disease Models, Animal,
pubmed-meshheading:17007839-Drug Synergism,
pubmed-meshheading:17007839-Male,
pubmed-meshheading:17007839-Maze Learning,
pubmed-meshheading:17007839-Mice,
pubmed-meshheading:17007839-Neuroprotective Agents,
pubmed-meshheading:17007839-Peptide Fragments,
pubmed-meshheading:17007839-Phosphodiesterase Inhibitors,
pubmed-meshheading:17007839-Pyrimidines,
pubmed-meshheading:17007839-Receptor, Adenosine A2A,
pubmed-meshheading:17007839-Treatment Outcome,
pubmed-meshheading:17007839-Triazoles
|
|
pubmed:year |
2007
|
|
pubmed:articleTitle |
Caffeine and adenosine A(2a) receptor antagonists prevent beta-amyloid (25-35)-induced cognitive deficits in mice.
|
|
pubmed:affiliation |
Departamento de Bioquímica, ICBS, UFRGS, Porto Alegre, Brazil.
|
|
pubmed:publicationType |
Journal Article,
Research Support, Non-U.S. Gov't
|
